Day: February 9, 2022

In week 6, Festi purchased in total 188,000 own shares for total amount of 43,616,000 ISK as follows:Week Date Time Purchased shares Price Purchase price Total shares bought Total puchase price6 7.2.2022 09:46:46 135.000 232 31.320.000 4.947.000 1.132.563.8606 8.2.2022 15:19:52 53.000 232 12.296.000 5.000.000 1.144.859.860      188.000   43.616.000    This announcement of purchase of own shares is in accordance with the buy-back programme announced 14 December 2021 to Nasdaq OMX Iceland. Festi has purchased in total 5,000,000 own shares for 1,144,859,860 ISK and has finished the buy-back. Before the purchase Festi held 6,000,000 own shares or 1.85% of issued shares but owns now 11,000,000 own shares or 3.40% of issued shares. The execution of the buy-back programme is in accordance with Chapter VIII of the Company Act...

Featured Image for Mastek Ltd.Featured Image for Mastek Ltd.READING, England, Feb. 09, 2022 (GLOBE NEWSWIRE) —  Mastek (NSE: MASTEK; BSE: 523704) announced today that it has appointed Damien Venkatasamy, Vivek Chopra and David O’Brien as subsidiary board members.  Hiral Chandrana, Global Chief Executive Officer, Mastek Group, said: “We are pleased to welcome Damien, David and Vivek to the Mastek family. They have joined Mastek at an exciting time as we drive our Vision 2025 strategy forward, build deeper relationships with clients in our growth markets and transform all stakeholder experiences with Digital.”  Ashank Desai, Vice Chairman, Co-Founder and MD, Mastek Group, said: “The addition of Damien, Vivek and David to our subsidiary boards complements strengths of our board of directors,...

SHENZHEN, China, Feb. 09, 2022 (GLOBE NEWSWIRE) — Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading mobile developer service provider in China, today announced that it was recently recognized as the Leading SaaS Enterprise in the ”2021 Fifth China Software and Information Service Industry Annual Billboard” (the “Annual Billboard”), an initiative by the Information Observation Network. The 2021 Annual Billboard aims to recognize outstanding products, services, solutions, enterprises and influential people across a variety of new and innovative technology including 5G application, industrial Internet, network security, cloud computing, AI, and the Internet of Things, which the organization believes will further promote the development and advancement of these sectors and other related industries. Since...

Lund, February 9, 2022 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced it has entered into an exclusive license agreement with Oncode Institute in the Netherlands, for the global rights to patents relating to the use of tasquinimod and other inhibitors of S100 for use in treatment of myelofibrosis (MF). Under the terms of the agreement, Oncode Institute, a foundation incorporated under the laws of the Netherlands, acting on behalf of Erasmus Universiteit Medisch Centrum (Erasmus MC), grants a global exclusive license to develop and commercialize tasquinimod worldwide in MF to Active Biotech. Active Biotech will pay to Oncode Institute, contingent of marketing approval, milestones as well as low single-digit royalties on net sales. Recently, Dr. Rebekka Schneiders group at Erasmus MC in Rotterdam published data showing...

Oslo, 9 February 2022: The board of directors of Scatec ASA (“Scatec“) has resolved to issue 53,257 shares to key employees following exercise of employee share options, pursuant to the company’s share option programme established in 2016 and prolonged in 2019. Through the share option exercise, Scatec is increasing the number of shares by 0.0335% to 158,917,275. Share capital after the option exercise: Scatec’s share capital will be increased with NOK 1,331.425 by issuing 30,379 new shares at a subscription price of NOK 69.99 and 22,878 new shares at a subscription price of NOK 112.79. Following completion of the share capital increase, the company’s share capital will be NOK 3,972,931.875 divided on 158,917,275 shares, each with a nominal value of NOK 0.025. For further information, please contact: Andreas Austrell, VP IR, tel: +47 974...

Former DANAHER, ROCHE & QIAGEN Business Development Executive with Over 25 Years of Experience within the Pharmaceuticals and Diagnostics Industry BERKELEY, Calif. and MAINZ, Germany, Feb. 09, 2022 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Dr. Rainer Metzger to its Strategic Advisory Board. “We’re thrilled to welcome Rainer who brings our Strategic Advisory Board significant senior level commercial experience within the field of oncology diagnostics,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “He will play a key role, supporting the Company’s clinical and commercial expansion through introductions to strategic commercial partners and exploration...

OP Mortgage BankFinancial Statements BulletinStock Exchange Release 9 February 2022 at 10.00 EET OP Mortgage Bank’s Financial Statements Bulletin for 1 January–31 December 2021 OP Mortgage Bank (OP MB) is part of OP Financial Group and its role is to raise, together with OP Corporate Bank plc, funding for OP from money and capital markets. OP MB is responsible for the Group’s funding for the part of covered bond issuance. Financial standing The intermediary loans and loan portfolio of OP MB totalled EUR 18,275 million (15,326)* on 31 December 2021. Bonds issued by OP MB totalled EUR 16,415 million (13,665) at the end of December 2021. In March, OP MB issued Finland’s first green covered bond in the international capital market. The fixed-rate EUR 750-million covered bond had a maturity of 10 years. Out of the proceeds of the...

The UK’s largest commercial source of news media audience will use Outbrain’s Smartfeed technology to grow revenue and drive engagement1XL Chooses Outbrain as its Exclusive Recommendation Technology Partner in Multi-Year Deal1XL Chooses Outbrain as its Exclusive Recommendation Technology Partner in Multi-Year DealLONDON, Feb. 09, 2022 (GLOBE NEWSWIRE) — Outbrain, a leading recommendation platform for the open web, today announced a new, multi-year deal with 1XL, the UK’s largest source of premium digital news media audiences as well as display inventory. 1XL, a division of Media Concierge and part of the Mediaforce Group, which owns the largest independent sales house in the UK, will adopt Outbrain as its exclusive recommendation provider. The strategic partnership will focus on growing revenue, supporting re-circulation...

February 9, 2022 – 21Shares AG (“21Shares”), the world’s largest issuer of cryptocurrency ETPs, today announced the launch of its fifth State of Crypto Report with a focus on Web 3.0 in this edition. The research report provides in-depth, data-driven insights on 21Shares’ assessment of the latest in the crypto industry, including the growth of crypto-native applications as part of the foundation-building of Web 3.0, an Internet of Value. Hany Rashwan, CEO and co-founder of 21Shares said, “We believe in publicly accessible research to drive further crypto adoption and build bridges between traditional finance and crypto finance. We are very pleased to present you with the latest in-depth research report and share our data-driven view on Web 3.0.” Web 3.0, the third evolution of the Internet, encapsulates a philosophy driven by decentralized...

VANCOUVER, British Columbia, Feb. 09, 2022 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that following its milestone announcement that its wholly-owned subsidiary, Vocan Biotechnologies Inc. (Vocan), has successfully engineered a novel recombinant production system for biologically synthesized (biosynthesized) psilocybin, and has filed for patent protection of its groundbreaking intellectual property (see Core One’s press release dated January 21, 2022), its team of scientist continue to make progress and are in the process of optimizing at scale production capacity. Scaled up production of the Company’s groundbreaking biosynthetic psilocybin, and an approval of the Company’s patent application will further Core One and Vocan’s...